FORMULATION DEVELOPMENT, OPTIMIZATION AND EVALUATION OF FAMOTIDINE FLOATING MATRIX TABLETS
Abstract
The purpose of this research work was to prepare a gastroretentive drug delivery system of Famotidine. This study investigated utility of a 3-factor, 3-level Box-Behnken design and optimization process for floating tablet of famotidine with 5 replicates of center points. Amount of HPMC K4 (Hydroxy Propyl Methyl cellulose), amount of NaHCO3 and amount of citric acid were selected as the independent variables whereas total floating time (TFT), half life, % cumulative drug release at 10 hrs, and diffusion coefficients (n) were selected as dependent variables. The prepared tablets of famotidine were evaluated for dissolution study and found to follow zero order release kinetic. The responses were analyzed using ANOVA and the individual response parameters were evaluated using F test and polynomial equation was generated for each response using MLRA. The amount of HPMC K4 and amount of citric acid were found to significantly influence all response parameters selected whereas the amount of NaHCO3 has significant effect on TFT. Optimum amount of HPMC K4, NaHCO3, and citric acid is important in achieving good floating time and minimum floating lag time. It was clear from dissolution profiles that the tablets of batch F3, F7, and F12 exhibits initial burst phase during the first hour of dissolution. The burst phase was followed by a limited drug release for the rest of the period. The produced tablets exhibited good floating time and controlled drug release over a period of 12 h. The resultant data were critically analyzed to locate the composition of optimum formulations. All predicted values of response variables of optimized formulation demonstrated close agreement with the experimental data during optimization procedure.
Keywords:
Famotidine, Gastroretentive floating tablet, Box-Behnken Design, Controlled release, Hydroxy Propyl Methyl Cellulose.DOI
https://doi.org/10.25004/IJPSDR.2009.010207References
2. Singh B, Kim K. formulation and evaluation of famotidine floating tablets. J Control Release 2000, 63: 235-59.
3. Coffin M, Parr A, inventors. Glaxo Inc. Ranitidine solid dosage form. US patent 5 407 687. April 18, 1995.
4. Nazzal S, Khan MA. Response surface methodology for the optimization of ubiquinone self-nanoemulsified drug delivery system. Pharm Sci Tech 2002; 3: 1-9.
5. Rosa M, Zia H, Rhodes T. Dosing and testing in-vitro of a bioadhesive and floating drug delivery system for oral application. Int J Pharm 1994; 105: 65-70.
6. The United State Pharmacopoeia 24, Asian edition, Rockville MD: United state pharmacopoeia convention Inc, 2000.
7. Pillay V, Fassihi R. Evaluation and comparison of dissolution data derived from different dosage forms: An alternative method. J Control Release 1998; 55:45-55.
8. Prakobvaitayaki M, Vimmannit V. Optimisation of polylactic-co-glycolic acid nanoparicles containing Itraconazole using 23 factorial designs. AAPS Pharm Sci Tech 2003; 4: 1-9.
9. Costa P, Lobo MS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001; 13: 123–33.
10. Colombo P, Bettini R, Santi P, Peppas NA. Swellable matrices for controlled drug delivery: Gel layer behavior, mechanisms and optimal performance. Pharm Sci Tech 2000; 3: 1-12.
11. Chuch HR. Optimization of sotalol floating and bioadhesive extended release tablet formulations. Drug Dev Ind Pharm 1995; 21(15): 1725-47.
12. Chavanpatil MD, Jain P, Chaudhari S, Shear R. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int J Pharmaceutics 2006; 304: 178–184.
Published
Abstract Display: 418 
PDF Downloads: 419 How to Cite
Issue
Section
Copyright (c) 2009 Manish P Patel, Madhabhai. M Patel, Dipti H Patel, Krishnakumar. N. Patel
This work is licensed under a Creative Commons Attribution 4.0 International License.
